Description
Pet Preferred Diagnostic offers a new universal highly specific and sensitive serological test for the detection eleven specific onconeural antibodies against intracellular neuronal antigens that are associated with twenty-two different tumors and fourteen neurological diseases. These antibodies, called onconeural or high-risk antibodies, can be found in patients with paraneoplastic neurological syndromes (PNS) which are well-defined as cancer-associated neurological diseases and characterized by severe and progressive neurological degeneration, remote from the tumor. Depending on the type of tumor, tumor cells express several antigens that can stimulate the formation of specific autoantibodies that are involved in the development of PNS, which precedes a tumor diagnosis.
It’s important to note that these onconeural antibodies can also be detected without a neurological syndrome and are specific for malignancy rather than for a particular neurological syndrome.
This test is the only one on the veterinary market that differentiates twenty-two different tumors and fourteen neurological diseases and is available for felines too. Dogs and cats with and without clinical signs should be screened for these diseases to detect possible tumours at a treatable stage. The test is an excellent tool to confirm or decline suspicion of having one of 22 tumors, to initiate a timely treatment and to monitor post-treatment.
RACE approved # 20-1259876
Learning Objectives
- To understand: The mechanism of the Early Cancer detection
- Why the detected antibodies are called “onconeural” or “high-risk”
- Who and why should be tested
- The test results and the explanation of the results
- The difference between Pet Preferred Diagnostics test and other cancer detection tests
- How to implement the test in your clinic
- How to send samples to Pet Preferred Diagnostics
